AI Verdict
SIGY has stronger fundamentals based on our AI analysis.
SIGY vs VIVS Fundamental Comparison
| Metric | SIGY | VIVS |
|---|---|---|
| Revenue | $4,590.0 | $131,000.0 |
| Net Income | $-2.7M | $-13.8M |
| Net Margin | -58,785.5% | -10,567.2% |
| ROE | N/A | N/A |
| ROA | -1,990.3% | -187.4% |
| Current Ratio | 0.02x | 2.38x |
| Debt/Equity | N/A | N/A |
| EPS | $-1.68 | $-5.35 |
Green = Better metric | Red = Weaker metric
You Might Also Compare
SIGY vs VIVS: Frequently Asked Questions
Is SIGY or VIVS the better stock in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), SIGY has stronger fundamentals. SIGY is graded D (98% confidence) while VIVS is graded D (96% confidence). This is not investment advice.
How does SIGY compare to VIVS fundamentally?
Sigyn Therapeutics, Inc. has ROE of N/A vs VivoSim Labs, INC.'s N/A. Net margins are -58,785.5% vs -10,567.2% respectively.
Which stock pays higher dividends, SIGY or VIVS?
SIGY has a dividend yield of N/A or no dividend while VIVS has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in SIGY or VIVS for long term?
For long-term investing, consider that SIGY has a D grade with 98% confidence, while VIVS has a D grade with 96% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about SIGY vs VIVS?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For SIGY vs VIVS, the AI consensus favors SIGY based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.